GlassScriptPhysician profile
Joshua David Loeb
NPI 1235372517
$6,980.36
in general payments reported to CMS, 2019-2025
11 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $958 · 2021: $1.66 · 2022: $4,047 · 2023: $958 · 2024: $135 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,398 · Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,398.00 |
| Food and Beverage | $411.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $5,893.62 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $677.13 | 2020-2025 | |
| Mallinckrodt Enterprises LLC | $139.08 | 2019 | |
| Sk Life Science, INC. | $131.65 | 2022-2024 | |
| Springworks Therapeutics, INC. | $33.79 | 2025 | Gomekli |
| Metacel Pharmaceuticals LLC | $29.16 | 2024 | Ozobax |
| Upsher-Smith Laboratories LLC | $25.44 | 2019 | |
| Ucb, INC. | $17.92 | 2024 | Nayzilam |
| Neurelis, INC. | $16.77 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.14 | 2020 | |
| Travere Therapeutics, INC. | $1.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Loeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.